Novo Nordisk A/S (ETR:NOV)
49.00
-1.80 (-3.54%)
Oct 10, 2025, 10:50 PM CET
Novo Nordisk Revenue
Novo Nordisk had revenue of 76.86B DKK in the quarter ending June 30, 2025, with 12.93% growth. This brings the company's revenue in the last twelve months to 311.94B, up 20.90% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
311.94B DKK
Revenue Growth
+20.90%
P/S Ratio
5.37
Revenue / Employee
4.03M DKK
Employees
77,349
Market Cap
224.36B EUR
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.22B |
Bayer Aktiengesellschaft | 46.17B |
Fresenius SE & Co. KGaA | 22.28B |
Fresenius Medical Care AG | 19.52B |
Sartorius Aktiengesellschaft | 3.47B |
Fielmann Group AG | 2.40B |
Carl Zeiss Meditec AG | 2.18B |
Novo Nordisk News
- 1 day ago - Novo Nordisk halts work on cell therapy for diabetes to cut costs, Bloomberg News reports - Reuters
- 2 days ago - Novo Nordisk A/S (NVO) M&A Call Transcript - Seeking Alpha
- 2 days ago - Novo Nordisk to acquire Akero Therapeutics for its experimental liver disease drug - Fast Company
- 2 days ago - Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion - Benzinga
- 2 days ago - Akero Therapeutics soars after Novo Nordisk set for $5.2B cash acquisition - Invezz
- 2 days ago - Akero Therapeutics Stock Soars on Novo Nordisk Deal. - Barrons
- 2 days ago - Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease - Market Watch
- 2 days ago - Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion - WSJ